UNDERSTANDING THE DISEASE COURSE OF PATIENTS WITH COVID-19 AND TYPE 2 DIABETES: A SCOPING REVIEW
Abstract
Background: The outbreak of Covid-19 since it was first identified in Wuhan has a tremendous global effect on many aspects of human life and it affects both developed and developing countries. Meanwhile, the prevalence of diabetes is also increasing along with the viral infection, hence, a review needs to be developed that can serve as the basis for clinical care improvements.
Design and methods: This scoping study review aims to explore the relationship between diabetes and Covid-19 condition using the latest relevant evidence.
Results: The findings revealed that after hypertension and cardiovascular diseases, diabetes is a major comorbid among patients with the virus. Based on the existing evidence, the comorbid disease has deleterious effects on the treatment course, morbidity, and clinical outcomes of Covid-19. Furthermore, some unique changes in immune responses have been identified, which exhibit different manifestations and interactions with standard diabetes treatments. Interactions have also been discovered between blood glucose, body mass index, and several hematological parameters, which correspond to the progression of the infection among diabetic patients.
Conclusion: Based on the results, Covid-19 triggered an exponential rise in the systemic inflammatory reaction, and patients with diabetes tend to have worse conditions, which were indicated by the increase in the ICU admission and mortality rate. Furthermore, the viral infection has various effects on the blood glucose stability of patients.
Downloads
References
Angelidi, A. M., Belanger, M. J., & Mantzoros, C. S. (2020). COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next. Metabolism: Clinical and Experimental, 107, 154245. https://doi.org/10.1016/j.metabol.2020.154245
Centre for Evidence-Based Medicine. (2020). Critical Appraisal tools — Centre for Evidence-Based Medicine (CEBM), University of Oxford. University of Oxford; University of Oxford. https://www.cebm.ox.ac.uk/resources/ebm-tools/critical-appraisal-tools
Clerkin, K. J., Fried, J. A., Raikhelkar, J., Sayer, G., Griffin, J. M., Masoumi, A., Jain, S. S., Burkhoff, D., Kumaraiah, D., Rabbani, L. R., Schwartz, A., & Uriel, N. (2020). COVID-19 and Cardiovascular Disease. Circulation, 2019, 1648–1655. https://doi.org/10.1161/CIRCULATIONAHA.120.046941
Dennis, J. M., Mateen, B. A., Sonabend, R., Thomas, N. J., Patel, K. A., Hattersley, A. T., Denaxas, S., McGovern, A. P., & Vollmer, S. J. (2021). Type 2 diabetes and covid-19– related mortality in the critical care setting: A national cohort study in england, march–july 2020. Diabetes Care, 44(1), 50–57. https://doi.org/10.2337/dc20-1444
Fauci, S., Kasper, D., Hauser, S., Longo, L., Losca;zo, L., & Jameson, J. (2014). Harrison’s Principles of Internal Medicine (19th ed.). McGraw-Hill Education.
Gao, Y., Liu, T., Zhong, W., Liu, R., Zhou, H., Huang, W., & Zhang, W. (2020). Risk of Metformin in Patients With Type 2 Diabetes With COVID-19: A Preliminary Retrospective Report. Clinical and Translational Science, 13(6), 1055–1059. https://doi.org/10.1111/cts.12897
Gregg, E. W., Sophiea, M. K., & Weldegiorgis, M. (2021). Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic. Diabetes Care, 44(9), 1916–1923. https://doi.org/10.2337/dci21-0001
Herman-Edelstein, M., Guetta, T., Barnea, A., Waldman, M., Ben-Dor, N., Barak, Y., Kornowski, R., Arad, M., Hochhauser, E., & Aravot, D. (2021). Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system. Cardiovascular Diabetology, 20(1), 90. https://doi.org/10.1186/s12933-021-01275-w
Hussain, A., Bhowmik, B., & do Vale Moreira, N. C. (2020). COVID-19 and diabetes: Knowledge in progress. Diabetes Research and Clinical Practice, 162(January). https://doi.org/10.1016/j.diabres.2020.108142
Lampasona, V., Secchi, M., Scavini, M., Bazzigaluppi, E., Brigatti, C., Marzinotto, I., Davalli, A., Caretto, A., Laurenzi, A., Martinenghi, S., Molinari, C., Vitali, G., Di Filippo, L., Mercalli, A., Melzi, R., Tresoldi, C., Rovere-Querini, P., Landoni, G., Ciceri, F., … Piemonti, L. (2020). Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. Diabetologia, 63(12), 2548–2558. https://doi.org/10.1007/s00125-020-05284-4
Lamptey, R., Ahomagnon, S., Acheampong, F., & Kalra, S. (2020). Glucovigilance in COVID-19 S-81 Diabetes : A Risk Factor for COVID-19. 70(5), 80–82.
Lei, M., Lin, K., Pi, Y., Huang, X., Fan, L., Huang, J., Liu, R., Liu, L., Shao, X., Hu, K., Yang, L., Qin, S., & He, F. (2020). Clinical Features and Risk Factors of ICU Admission for COVID-19 Patients with Diabetes. Journal of Diabetes Research, 2020. https://doi.org/10.1155/2020/5237840
Lisco, G., De Tullio, A., Giagulli, V. A., Guastamacchia, E., De Pergola, G., & Triggiani, V. (2020). Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review. Endocrine, 70(3), 441–453. https://doi.org/10.1007/s12020-020-02444-9
Li, Y., Han, X., Alwalid, O., Cui, Y., Cao, Y., Liu, J., Gu, J., Wang, L., Fan, Y., & Shi, H. (2020). Clinical characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study. Diabetes Research and Clinical Practice, 166(July), 1382–1392. https://doi.org/10.1016/j.diabres.2020.108299
Longmore, D. K., Miller, J. E., Bekkering, S., Saner, C., Mifsud, E., Zhu, Y., Saffery, R., Nichol, A., Colditz, G., Short, K. R., & Burgner, D. P. (2021). Diabetes and Overweight/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of COVID-19: An International, Multicenter Retrospective Meta-analysis. Diabetes Care, 44(6), 1281–1290. https://doi.org/10.2337/dc20-2676
Mirsoleymani, S., Taherifard, E., Taherifard, E., Taghrir, M. H., & Marzaleh, M. A. (2021). Predictors of Mortality Among COVID-19 Patients With or Without Comorbid Diabetes Mellitus. Acta Medica Iranica, 2020(March 2020).
Pal, R., Sachdeva, N., Mukherjee, S., & Suri, V. (2020). Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: A preliminary report. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, January.
Pérez-Belmonte, L. M., Torres-Peña, J. D., López-Carmona, M. D., Ayala-Gutiérrez, M. M., Fuentes-Jiménez, F., Huerta, L. J., Muñoz, J. A., Rubio-Rivas, M., Madrazo, M., Garcia, M. G., Montes, B. V., Sola, J. F., Ena, J., Ferrer, R. G., Pérez, C. M., Ripper, C. J., Lecumberri, J. J. N., Acedo, I. E. A., Canteli, S. P., … Gómez-Huelgas, R. (2020). Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Medicine, 18(1), 1–11. https://doi.org/10.1186/s12916-020-01832-2
Peric, S., & Stulnig, T. M. (2020). Diabetes and COVID-19 Disease — Management — People. 356–361.
Pugliese, G., Vitale, M., Resi, V., & Orsi, E. (2020). Is diabetes mellitus a risk factor for COronaVIrus Disease 19 (COVID-19)? Acta Diabetologica, 57(11), 1275–1285. https://doi.org/10.1007/s00592-020-01586-6Sardu, C., Gargiulo, G., Esposito, G., Paolisso, G., & Marfella, R. (2020). Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19. Cardiovascular Diabetology, 19(1), 1–5. https://doi.org/10.1186/s12933-020-01047-y
Seiglie, J., Platt, J., Cromer, S. J., Bunda, B., Foulkes, A. S., Bassett, I. V., Hsu, J., Meigs, J. B., Leong, A., Putman, M. S., Triant, V. A., Wexler, D. J., & Manne-Goehler, J. (2020). Diabetes as a risk factor for poor early outcomes in patients hospitalized with covid-19. Diabetes Care, 43(12), 2938–2944. https://doi.org/10.2337/dc20-1506
Sun, Y., Zhao, R., Hu, Z., Wang, W., Wang, S., Gao, L., Fei, J., Jian, X., Li, Y., Zheng, H., Hou, X., & Chen, L. (2020). Differences in the Clinical and Hematological Characteristics of COVID-19 Patients with and without Type 2 Diabetes. Journal of Diabetes Research, 2020. https://doi.org/10.1155/2020/1038585
Wallett, L., Kempegowda, P., Melson, E., Juszczak, A., Thomas, L., Zhou, D., Holmes, C., Karamat, M. A., Ghosh, S., Hanif, W., Johnson, A., Narendran, P., & Bellary, S. (2021). Differences in presentation, severity and management of DKA in type 1 and type 2 diabetes during the COVID-19 pandemic. Clinical Medicine, Journal of the Royal College of Physicians of London, 21, 1–3. https://doi.org/10.7861/clinmed.21-2-s1
World Health Organization. (2021). WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. In Who (pp. 1–5). https://covid19.who.int/
Yan, Y., Yang, F., Zhu, X., Wang, M., Sun, Z., Zhao, T., Yang, X., & Zou, Y. (2020). Analysis of clinical features and pulmonary CT features of coronavirus disease 2019 (COVID-19) patients with diabetes mellitus. Endokrynologia Polska, 71(5), 367–375. https://doi.org/10.5603/EP.A2020.0055
Zhao, R., Sun, Y., Zhang, Y., Wang, W., Wang, S., Wang, C., Liu, J., Gao, L., Hu, Z., Fei, J., Hou, X., Zheng, H., & Chen, L. (2020). Distinguishable Immunologic Characteristics of COVID-19 Patients with Comorbid Type 2 Diabetes Compared with Nondiabetic Individuals. Mediators of Inflammation, 2020. https://doi.org/10.1155/2020/6914878
Zheng, M., Wang, X., Guo, H., Fan, Y., Song, Z., Lu, Z., Wang, J., Zheng, C., Dong, L., Ma, Y., Zhu, Y., Fang, H., & Ye, S. (2021). The Cytokine Profiles and Immune Response Are Increased in COVID-19 Patients with Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2021. https://doi.org/10.1155/2021/9526701
Zhou, W., Ye, S., Wang, W., Li, S., & Hu, Q. (2020). Clinical Features of COVID-19 Patients with Diabetes and Secondary Hyperglycemia. Journal of Diabetes Research, 2020(Dm). https://doi.org/10.1155/2020/3918723
Copyright (c) 2023 Ahmad J, Ahmad Hasyim Wibisono, Ayu Nanda Lestari
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
